Massachusetts General Hospital
Hematopoietic Stem Cell Transplant
& Cellular Therapy Program
55 Fruit Street, Yawkey 9E
Boston, MA 2114
Direct phone: (617) 724-1124
Total transplants by cell source
- Marrow: 13
- PBSC: 176
- Cord Blood: 0
- Autologous (PBSC or Marrow): 119
About the center
MGH is a FACT accredited program. The Hematopoietic Cell Transplant and Cellular Therapy (HCTCT) program offers a comprehensive range of transplant services including myeloablative and reduced intensity matched related and unrelated donor transplants, cord blood transplants and haploidentical donor transplants as well as recent advances in gene modified autologous cellular therapy products such as chimeric antigen receptor T-cells (CAR-T). Our program has state of the art facilities for both inpatient and outpatient care that includes a 32 bed inpatient unit. This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since 2007.
This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since October 2007.
Adult - Yi Bin Chen, Zachariah DeFilipp, Bimal Dey, Areej El-Jawahri, Matthew Frigault, Mark Leick, Steven McAfee, Paul O'Donnell, Thomas Spitzer
Marrow/PBSC and double cord
Cord blood transplants performed on
Other programs and services
For additional information please visit: https://www.massgeneral.org/cancer-center/treatments-and-services/bone-marrow-transplant
Overall center survival
Patient survival information for this center
This center's actual 1-year survival results are above the expected rate for this center.
The survival information we have for this center includes ONLY:
- Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
- Who had their transplant at a U.S. transplant center, and
- Who had follow-up information provided by the transplant center for analysis
For this center, we have survival information for 264 patients.
The actual 1-year survival of these patients is 82.1%.
Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 71.5% and 81.4%.
For help with understanding these statistics, please see Understanding Transplant Outcomes.
For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.
Transplants reported (From January 1, 2020 to December 31st, 2021 as reported by the centers)
|Both marrow & PBSC
Transplants by disease
Number of transplants by age reported from January 1, 2020 to December 31st, 2021 (includes marrow, PBSC and cord blood)
Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.
Centers are not required to report autologous transplants so the numbers might be incomplete.
More information about transplants for this disease can be found:
Transplant center resources
Transplant center coordinator:
Be The Match patient navigators
Patient navigators can answer your questions about choosing a transplant center and provide support and education to help you throughout your transplant journey.
Inside the United States: 1 (888) 999-6743
Outside the United States: 1 (763) 406-3410.
(Long distance or international charges may apply.)